Invention Grant
- Patent Title: Dual targeting of TAFI and PAI-1
-
Application No.: US15117027Application Date: 2015-02-09
-
Publication No.: US10239953B2Publication Date: 2019-03-26
- Inventor: Paul Declerck , Simon De Meyer , Nick Geukens , Ann Gils , Marina Rubio , Denis Vivien , Tine Wyseure
- Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN , INSERM (Institut National de la Santé et de la Recherche Médicale) , Université de Caen Basse Normandie , Centre Hospitalier Universitaire de Caen
- Applicant Address: BE Leuven FR Paris FR Caen FR Caen
- Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN,INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ DE CAEN BASSE NORMANDIE,CENTRE HOSPITALIER UNVIERSITAIRE DE CAEN
- Current Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN,INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ DE CAEN BASSE NORMANDIE,CENTRE HOSPITALIER UNVIERSITAIRE DE CAEN
- Current Assignee Address: BE Leuven FR Paris FR Caen FR Caen
- Agency: Workman Nydegger
- Priority: GB1404879.7 20140319; GB1404880.5 20140319; GB1411979.6 20140704; GB1422609.6 20141218
- International Application: PCT/EP2015/052624 WO 20150209
- International Announcement: WO2015/118147 WO 20150813
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/38 ; A61K39/00
Abstract:
Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).
Public/Granted literature
- US20170253664A2 DUAL TARGETING OF TAFI AND PAI-1 Public/Granted day:2017-09-07
Information query
